Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01040091 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01040091 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 34 participants.
The verdict
NCT01040091, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are two antiretroviral medications used for the treatment and prevention of HIV/AIDS. This study will examine how these medications are processed in the body of people who are HIV-infected, as well as in people who are HIV-uninfected.
Interventions
- DRUG Truvada
- DRUG Efavirenz (EFV)
- DRUG Emtricitabine (FTC)
- DRUG Tenofovir disoproxil fumarate (TDF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01040091
The ClinicalTrials.gov registry entry for NCT01040091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Truvada is the first listed.
NCT01040091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01040091 about?
NCT01040091 is a clinical study titled "Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status". Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are two antiretroviral medications used for the treatment and prevention of HIV/AIDS. This study will examine how these medications are processed in the body of people who are HIV-infected, as well as in people who are HIV-uninfected.
What is the current status of trial NCT01040091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2009-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01040091?
The interventions under investigation include: Truvada (DRUG), Efavirenz (EFV) (DRUG), Emtricitabine (FTC) (DRUG), Tenofovir disoproxil fumarate (TDF) (DRUG).
Who is sponsoring clinical trial NCT01040091?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.